Dolutegravir + Emtricitabine + Tenofovir Alafenamide
Composition
The formulation contains Tenofovir Alafenamide 25 mg + Emtricitabine 200mg + Dolutegravir 40mg Tablet: Contains tenofovir alafenamide 25mg, emtricitabine 200mg, and dolutegravir 40mg as the active ingredients.
Indications
HIV-1 infection treatment
Side effects
Insomnia, headache, gastrointestinal symptoms
Precautions
Monitor for renal function and risk of opportunistic infections
Contraindications
Co-administration with dofetilide, rifampin, Hypersensitivity to any component of the product
Dosage and administration
One tablet daily
Countries
USA, UK, Australia
Available Forms
Tablets
Manufacturing Services
Third Party Manufacturing Company WHO, GMP, EUGMP, USFDA, In India | Contract Manufacturing Organization (CMO) WHO, GMP, EUGMP, USFDA Services in India, Mumbai, Navi Mumbai| Contract Development and Manufacturing Organization (CDMO) WHO, GMP, EUGMP, USFDA - Services in India | Pharmaceutical Contract Manufacturing Company WHO, GMP, EUGMP, USFDA in Navi Mumbai, India | Top Pharmaceutical Product Exporters, Suppliers, Distributer WHO, GMP, EUGMP, USFDA in Mumbai